Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelo...
20 Loka 20231h 1min
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relap...
19 Loka 20231h 1min
Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences
Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.
18 Loka 20231h 19min
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar
Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lym...
12 Loka 202346min
What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma
Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by...
9 Loka 202347min
Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm
Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms.
5 Loka 202333min
Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma
Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multipl...
28 Syys 202339min
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houst...
22 Syys 20231h 2min
